Search

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

FDA Grants Priority Review to Boehringer Ingelheim’s Biologics License Application for Idarucizumab*

Boehringer Ingelheim Celebrates 50th Anniversary in the U.S. by Committing Up to $450,000 to Nonprofit Partners

FDA Grants OFEV® (nintedanib) BTD for Chronic Fibrosing ILDs | Boehringer Ingelheim US

FDA grants Breakthrough Therapy Designation to OFEV for chronic fibrosing ILDs with a progressive phenotype. View ISI, PI and Med Guide.

FDA approves Ofev® as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD

Xochimilco

With its presence in Greece of more than a half century,

BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US

Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.

Boehringer Ingelheim launches vaccine to protect poultry from three diseases

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Phase III study showed Ofev® slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Phase III study showed Ofev slows the loss of pulmonary function in people living with systemic sclerosis associated ILD

Ingelheim

The company headquarters of Boehringer Ingelheim are located in Ingelheim, Germany.

Clinical Pharmacology

Boehringer Ingelheim is proud to offer a new two-year fellowship within Clinical Pharmacology. Click here to find out more.

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Biberach

Click here to view our Biberach site, in Southern Germany, home to the largest research & development center within Boehringer Ingelheim’s global network.

Jardiance® (empagliflozin) Lessened Risk of Heart Failure | Boehringer Ingelheim US

The EMPRISE real-world study shows JARDIANCE saw a decreased risk of hospitalization for heart failure. View ISI, PI and Med Guide.

Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure

Data Shows Jardiance® (empagliflozin) Cardiorenal Risk Reductions | Boehringer Ingelheim US

The EMPA-REG OUTCOME® trial shows JARDIANCE reduces CV and renal risk in adults with T2D & known CV disease. View ISI, PI & Med Guide.

New consortium EUbOPEN will provide tools to unlock disease biolog

Boehringer Ingelheim Advances First Pan-KRAS Inhibitor BI 1701963 into Clinical Testing

Jardiance® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.

BI Starts Clinical Study on Interchangeability | Boehringer Ingelheim US

BI announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study, for an adalimumab biosimilar candidate.

Jardiance® (empagliflozin) analysis reinforces established safety profile

IPF patients treated with Ofev® (nintedanib) versus placebo were twice as likely to have improved or stable lung function

Boehringer Ingelheim Presents First Head-to-Head Matched Population Comparison

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers